Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19262983 | 0.85 | MAPT (0.44) | MAPTSMN1; SMN2ALDH1A1MEN1GAA | |
| SCHEMBL19102463 | 0.84 | NPC1 (0.35) | MAPTSMN1; SMN2 | |
| SCHEMBL24627783 | 0.84 | — | — | |
| SCHEMBL20852892 | 0.77 | CYP3A4 (0.41) | MAPTALDH1A1GAAPKMKDM4E | |
| SCHEMBL24023635 | 0.73 | TYR (0.34) | ALDH1A1GAA | |
| SCHEMBL32671491 | 0.71 | MAPT (0.42) | MAPTSMN1; SMN2ALDH1A1MEN1GAA | |
| SCHEMBL183161 | 0.71 | MAPT (0.42) | MAPTSMN1; SMN2ALDH1A1MEN1GAA | |
| SCHEMBL19102536 | 0.70 | MAPT (0.39) | MAPTSMN1; SMN2ALDH1A1MEN1GAA | |
| SCHEMBL11541907 | 0.69 | MAPT (0.41) | MAPTSMN1; SMN2ALDH1A1MEN1GAA | |
| SCHEMBL11543698 | 0.69 | ALDH1A1 (0.43) | MAPTSMN1; SMN2ALDH1A1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124501-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-09-21 | — | — | US | disclosed |
| US-10647678-B2 | Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-12 | — | — | US | disclosed |
| US-20190106413-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-04-11 | — | — | US | disclosed |
| US-10189821-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-20180093955-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-04-05 | — | — | US | disclosed |
| US-20170037036-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR I | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106413-A1 | INHIBITOR COMPOUNDS | HSF1, HSP90AB1, HSP90AA1 | MAPT 1193/4885SMN1; SMN2 3616/4885ALDH1A1 879/4885 |
| US-20180093955-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY | HSF1, HSP90AB1, HSP90AB2P | MAPT 2433/4885SMN1; SMN2 3851/4885ALDH1A1 1637/4885 |
| US-10647678-B2 | Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity | HSF1, HSP90AB1, HSP90AB2P | MAPT 2433/4885SMN1; SMN2 3851/4885ALDH1A1 1637/4885 |
| US-10189821-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I | HSF1, HSP90AB1, HSPB1 | MAPT 2665/4885SMN1; SMN2 3744/4885ALDH1A1 541/4885 |
| US-20170037036-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR I | HSF1, HSP90AB1, HSPB1 | MAPT 2665/4885SMN1; SMN2 3744/4885ALDH1A1 541/4885 |
| US-11124501-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I | HSF1, HSP90AB1, HSPB1 | MAPT 2665/4885SMN1; SMN2 3744/4885ALDH1A1 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.